Cell Signaling Technology

Product Pathways - Tyrosine Kinase/ Adaptors

Met (25H2) Mouse mAb #3127

Applications Reactivity MW (kDa) Source Isotype
W IP H M R Mk 145 mature Met beta-subunit. 170 pro-Met. Mouse IgG1

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Met (25H2) Mouse mAb detects endogenous levels of Met protein.

Source / Purification

Monoclonal antibody is produced by immunizing mice with a synthetic peptide (KLH-coupled) corresponding to residues surrounding Tyr1234 of human Met.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines: mIMCD3 (lane 1), Vero (lane 2), 293 (HGF stimulated; lane 3) 293 (starved; lane 4) and C6 (lane 5), using Met (25H2) Mouse mAb.

Background

Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor), is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. Addition of a phosphate at cytoplasmic Tyr1003 is essential for ubiquitination and Met protein degradation (4). Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon and breast. Thus, Met is an attractive cancer therapeutic and diagnostic target (6).

  1. Weidner, K.M. et al. (1993) J. Cell Biol. 121, 145-154.
  2. Park, M. et al. (1986) Cell 45, 895-904.
  3. Bardelli, A. et al. (1997) Oncogene 15, 3103-3111.
  4. Taher, T.E. et al. (2002) J. Immunol. 169, 3793-3800.
  5. Schaeper, U. et al. (2000) J. Cell Biol. 149, 1419-1432.
  6. Traxler, P. et al. (2001) Med. Res. Rev. 21, 499-512.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes